英国成人高血压患者晚间与晨间服用常规降压药的心血管结局(TIME研究):一项前瞻性、随机、开放标签、盲法终点临床试验
主要复合终点(血管性死亡或非致死性心肌梗死或非致死性卒中的住院)在晚间组发生362例(3.4%),晨间组390例(3.7%),未校正HR 0.95(95%CI 0.83-1.10;p=0.53),两组无差异,未发现安全性问题。
要点
- 晚间服药组主要终点事件362例(3.4%),晨间组390例(3.7%),未校正HR 0.95(95%CI 0.83-1.10;p=0.53)。
- 晚间服用常规降压药在主要心血管结局方面与晨间服用无差异。
- 患者可在方便且能尽量减少不良影响的时间服用常规降压药。
核心结论
- 晚间服用常规降压药在主要心血管结局方面与晨间服用无差异。
- 患者可在方便且能尽量减少不良影响的时间服用常规降压药。
研究设计与样本
- TIME研究为在英国开展的前瞻性、实用性、去中心化、平行组研究。
- 招募年龄≥18岁、正在服用至少一种降压药的高血压成人,按1:1随机分配,无限制、分层或最小化。
- 参与者将全部常规降压药安排在晨间(0600-1000时)或晚间(2000-0000时)服用。
- 主要终点为血管性死亡或非致死性心肌梗死或非致死性卒中的住院复合终点,在意向治疗人群中评估至首次发生事件的时间。
- 2011年12月17日至2018年6月5日筛查24610人,随机分配21104人至晚间组(n=10503)或晨间组(n=10601)。
主要发现
- 研究入组时平均年龄65.1岁(SD 9.3);12136例(57.5%)为男性,8968例(42.5%)为女性;19101例(90.5%)为白人,98例(0.5%)为黑人、非洲人、加勒比人或英国黑人(1637例[7.8%]未报告族裔);2725例(13.0%)有既往心血管疾病。
- 截至研究随访结束(2021年3月31日),中位随访5.2年(IQR 4.9-5.7),晚间治疗组10503例中529例(5.0%)退出全部随访,晨间治疗组10601例中318例(3.0%)退出全部随访。
- 主要终点事件在晚间治疗组发生362例(3.4%)(每100患者年0.69次事件[95%CI 0.62-0.76]),在晨间治疗组发生390例(3.7%)(每100患者年0.72次事件[95%CI 0.65-0.79];未校正风险比0.95[95%CI 0.83-1.10];p=0.53)。
- 未发现安全性问题。
临床怎么用
- 作者认为,患者可在方便且能尽量减少不良影响的时间服用常规降压药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies have suggested that evening dosing with antihypertensive therapy might have better outcomes than morning dosing. The Treatment in Morning versus Evening (TIME) study aimed to investigate whether evening dosing of usual antihypertensive medication improves major cardiovascular outcomes compared with morning dosing in patients with hypertension. METHODS: The TIME study is a prospective, pragmatic, decentralised, parallel-group study in the UK, that recruited adults (aged ≥18 years) with hypertension and taking at least one antihypertensive medication. Eligible participants were randomly assigned (1:1), without restriction, stratification, or minimisation, to take all of their usual antihypertensive medications in either the morning (0600-1000 h) or in the evening (2000-0000 h). Participants were followed up for the composite primary endpoint of vascular death or hospitalisation for non-fatal myocardial infarction or non-fatal stroke. Endpoints were identified by participant report or record linkage to National Health Service datasets and were adjudicated by a committee masked to treatment allocation. The primary endpoint was assessed as the time to first occurrence of an event in the intention-to-treat population (ie, all participants randomly assigned to a treatment group). Safety was assessed in all participants who submitted at least one follow-up questionnaire. The study is registered with EudraCT (2011-001968-21) and ISRCTN (18157641), and is now complete. FINDINGS: Between Dec 17, 2011, and June 5, 2018, 24 610 individuals were screened and 21 104 were randomly assigned to evening (n=10 503) or morning (n=10 601) dosing groups. Mean age at study entry was 65·1 years (SD 9·3); 12 136 (57·5%) participants were men; 8968 (42·5%) were women; 19 101 (90·5%) were White; 98 (0·5%) were Black, African, Caribbean, or Black British (ethnicity was not reported by 1637 [7·8%] participants); and 2725 (13·0%) had a previous cardiovascular disease. By the end of study follow-up (March 31, 2021), median follow-up was 5·2 years (IQR 4·9-5·7), and 529 (5·0%) of 10 503 participants assigned to evening treatment and 318 (3·0%) of 10 601 assigned to morning treatment had withdrawn from all follow-up. A primary endpoint event occurred in 362 (3·4%) participants assigned to evening treatment (0·69 events [95% CI 0·62-0·76] per 100 patient-years) and 390 (3·7%) assigned to morning treatment (0·72 events [95% CI 0·65-0·79] per 100 patient-years; unadjusted hazard ratio 0·95 [95% CI 0·83-1·10]; p=0·53). No safety concerns were identified. INTERPRETATION: Evening dosing of usual antihypertensive medication was not different from morning dosing in terms of major cardiovascular outcomes. Patients can be advised that they can take their regular antihypertensive medications at a convenient time that minimises any undesirable effects. FUNDING: British Heart Foundation.
引用
- Mackenzie IS, Rogers A, Poulter NR, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022. PMID: 36240838. doi:10.1016/S0140-6736(22)01786-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。